|
1) Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology. 2010; 139: 393-408. [Epub ahead of print]
|
|
|
|
2) 生田克哉, 鳥本悦宏, 高後 裕. 輸血後鉄過剰症の病態と症状. 血液・腫瘍科. 2009; 59: 522-7
|
|
|
|
|
|
3) Takatoku M, Uchiyama T, Okamoto S, et al (Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes). Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol. 2007; 78: 487-94
|
|
|
|
|
4) 厚生労働科学研究費補助金 難治性疾患克服研究事業 特発性造血障害に関する調査研究班(平成20年度)(研究代表者 小澤敬也). 輸血後鉄過剰症の診療ガイド. 2008
|
|
|
|
|
|
5) Tehranchi R, Invernizzi R, Grandien A, et al. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood. 2005; 106: 247-53
|
|
|
|
|
|
6) Ghoti H, Amer J, Winder A, et al. Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome. Eur J Haematol. 2007; 79: 463-7
|
|
|
|
|
|
7) Amer J, Ghoti H, Rachmilewitz E, et al. Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants. Br J Haematol. 2006; 132: 108-13
|
|
|
|
|
|
8) Ito K, Hirao A, Arai F, et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med. 2006; 12: 446-51
|
|
|
|
|
|
9) Kohgo Y, Ikuta K, Ohtake T, et al. Body iron metabolism and pathophysiology of iron overload. Int J Hematol. 2008; 88: 7-15
|
|
|
|
|
10) Tziomalos K, Perifanis V. Liver iron content determination by magnetic resonance imaging. World J Gastroenterol. 2010; 16: 1587-97
|
|
|
|
|
|
11) Jensen PD. Evaluation of iron overload. Br J Haematol. 2004; 124: 697-711
|
|
|
|
|
|
12) Mavrogeni SI, Markussis V, Kaklamanis L, et al. A comparison of magnetic resonance imaging and cardiac biopsy in the evaluation of heart iron overload in patients with beta-thalassemia major. Eur J Haematol. 2005; 75: 241-7
|
|
|
|
|
|
13) Park J, Ohyashiki K, Akata S, et al. Evaluation of cardiac iron overload in transfusion-dependent adult marrow failure patients by magnetic resonance imaging. Leuk Res. 2009; 33: 756-8
|
|
|
|
|
|
14) Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2＊ mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005; 106: 1460-5
|
|
|
|
|
|
15) Kirk P, Roughton M, Porter JB, et al. Cardiac T2＊ magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009; 120: 1961-8
|
|
|
|
|
|
16) Noetzli LJ, Carson SM, Nord AS, et al. Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008; 112: 2973-8
|
|
|
|
|
|
17) Papakonstantinou O, Alexopoulou E, Economopoulos N, et al. Assessment of iron distribution between liver, spleen, pancreas, bone marrow, and myocardium by means of R2 relaxometry with MRI in patients with beta-thalassemia major. J Magn Reson Imaging. 2009; 29: 853-9
|
|
|
|
|
|
18) Au W, Lam W, Chu W, et al. A pilot MRI study of organ specific hemosiderosis and functional correlation in Chinese patients with myelodysplasia and aplastic anemia with raised ferritin levels. Hematol Oncol. 2008; 26: 225-8
|
|
|
|
|
|
19) Konen E, Ghoti H, Goitein O, et al. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique. Am J Hematol. 2007; 82: 1013-6
|
|
|
|
|
|
20) Chacko J, Pennell DJ, Tanner MA, et al. Myocardial iron loading by magnetic resonance imaging T2＊ in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol. 2007; 138: 587-93
|
|
|
|
|
|
21) Fischer R, Piga A, Harmatz P, et al. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Ann NY Acad Sci. 2005; 1054: 350-7
|
|
|
|
|
|
22) Avrin WF, Kumar S. Noninvasive liver-iron measurements with a room-temperature susceptometer. Physiol Meas. 2007; 28: 349-61
|
|
|
|
|
|
23) Ozment CP, Turi JL. Iron overload following red blood cell transfusion and its impact on disease severity. Biochim Biophys Acta. 2009; 1790: 694-701
|
|
|
|
|
|
24) Piga A, Longo F, Duca L, et al. High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol. 2009; 84: 29-33
|
|
|
|
|
|
25) Taher A, Musallam KM, El Rassi F, et al. Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassemia intermedia. Br J Haematol. 2009; 146: 569-72
|
|
|
|
|
|
26) Cappellini MD. Long-term efficacy and safety of deferasirox. Blood Rev. 2008; 22 (Suppl 2): S35-S41
|
|
|
|
|
|
27) Cappellini MD, El-Beshlawy A, Kattamis A, et al. Efficacy and safety of deferasirox(Exjade®)in patients with transfusion-dependent anemias: 1-year results from the large, prospective, multicenter EPIC study. Presented at the Annual Meeting of the American Society of Hematology. December 6-9, 2008; San Francisco, California. Poster III-957
|
|
|
|
|
|
28) Metzgeroth G, Dinter D, Schultheis B, et al. Deferasirox in MDS patients with transfusion-caused iron overload-a phase-II study. Ann Hematol. 2009; 88: 301-10
|
|
|
|
|
|
29) Wimazal F, Nösslinger T, Baumgartner C, et al. Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes. Eur J Clin Invest. 2009; 39: 406-11
|
|
|
|
|
|
30) Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassemia: the ESCALATOR study. Eur J Haematol. 2009; 82: 458-65
|
|
|
|
|
|
31) Pennell D, Sutcharitchan P, El-Beshlawy A, et al. Efficacy and safety of deferasirox(Exjade®)in preventing cardiac iron overload in b-thalassemia patients with normal baseline cardiac iron: results from the cardiac substudy of the EPIC trial. Presented at the Annual Meeting of the American Society of Hematology. December 6-9, 2008; San Francisco, California. Poster III-956
|
|
|
|
|
|
32) Ghoti H, Fibachi E, Merkel D, et al. Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes. Haematologica. 2010; 95: 1433-4
|
|
|
|
|
|
33) List AF, Baer MR, Steensma D, et al. Deferasirox(ICL670 Exjade®)reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndromes (MDS) [abstract]. Blood. 2007; 110: 440a. Abstract 1470
|
|
|
|
|
|
34) Jensen PD, Heickendorff L, Pederson B, et al. The effect of iron chelation on haematopoiesis in MDS patients with transfusional iron overload. Br J Haematol. 1996; 94: 288-99
|
|
|
|
|
|
35) Oliva EN, Ronco F, Marino A, et al. Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion. 2010; 50: 1568-70
|
|
|
|
|
|
36) Messa E, Cilloni D, Messa F, et al. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol. 2008; 120: 70-4
|
|
|
|
|
|
37) Di Tucci AA, Murru R, Alberti D, et al. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox(Exjade, ICL670). Eur J Haematol. 2007; 78 540-2
|
|
|
|
|
|
38) Park SJ, Han CW. Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis. J Korean Med Sci. 2008; 23: 320-3
|
|
|
|
|
|
39) 岡部 寛, 鈴木隆浩, 大森 司, 他. 輸血後鉄過剰症に対するICL670 (deferasirox) 投与により造血能の回復が得られた骨髄異形成症候群. 臨床血液. 2009; 50: 1626-9
|
|
|
|
|
40) Rose C, Brechignac S, Vassilief D, et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM [abstract]. Blood. 2007; 110: 80a. Abstract 249
|
|
|
|
|